The Valley Desk

NCT04637763 · Interventional trial

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Overall registry status Active not recruiting

Phase 1

Conditions B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov